20171109 Transgene_Private placement
Category: Press release
Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
20171030 PR SITC TG4010
First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
20171026-PR-TG6002
TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
20171023 PR post AASLD TG1050 final. docx
Third Quarter Marked by Progress in Clinical Development and Research
171019 PR Q3-2017 FINAL
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
20171017 PR AASLD TG1050 final
Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
20171012 PR TG4010 publications
Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
20171002-PR-TG-Randox-final
Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
20170905 Invirio PR US
First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
170919-Transgene-FPI-Announcement_US